{"title":"PSMA PET-CT 显示的区域内异质性可预测 mCRPC 的预后","authors":"Maria Chiara Masone","doi":"10.1038/s41585-024-00943-2","DOIUrl":null,"url":null,"abstract":"<p>Intra-tumour heterogeneity in patients with metastatic castration-resistant prostate cancer (mCRPC) poses a challenge to treatment, owing to variability in tumour growth and response to therapy. Currently available tools such as response evaluation criteria in solid tumors (RECIST) and circulating tumour DNA (ctDNA) are useful methods to measure patient response to treatment but do not enable the assessment of individual tumour lesions with high resolution.</p><p>In a new study published in <i>Med</i>, the potential of <sup>68</sup>Ga-prostate-specific membrane antigen (PSMA) + <sup>18</sup>F-fluorodeoxyglucose (FDG) paired positron emission tomography–computed tomography (PET–CT) was assessed to capture intralesional response heterogeneity (ILRH) and improve risk stratification in patients with mCRPC.</p>","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":null,"pages":null},"PeriodicalIF":12.1000,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Intralesional heterogeneity on PSMA PET–CT predicts mCRPC outcomes\",\"authors\":\"Maria Chiara Masone\",\"doi\":\"10.1038/s41585-024-00943-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Intra-tumour heterogeneity in patients with metastatic castration-resistant prostate cancer (mCRPC) poses a challenge to treatment, owing to variability in tumour growth and response to therapy. Currently available tools such as response evaluation criteria in solid tumors (RECIST) and circulating tumour DNA (ctDNA) are useful methods to measure patient response to treatment but do not enable the assessment of individual tumour lesions with high resolution.</p><p>In a new study published in <i>Med</i>, the potential of <sup>68</sup>Ga-prostate-specific membrane antigen (PSMA) + <sup>18</sup>F-fluorodeoxyglucose (FDG) paired positron emission tomography–computed tomography (PET–CT) was assessed to capture intralesional response heterogeneity (ILRH) and improve risk stratification in patients with mCRPC.</p>\",\"PeriodicalId\":19088,\"journal\":{\"name\":\"Nature Reviews Urology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":12.1000,\"publicationDate\":\"2024-09-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41585-024-00943-2\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41585-024-00943-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Intralesional heterogeneity on PSMA PET–CT predicts mCRPC outcomes
Intra-tumour heterogeneity in patients with metastatic castration-resistant prostate cancer (mCRPC) poses a challenge to treatment, owing to variability in tumour growth and response to therapy. Currently available tools such as response evaluation criteria in solid tumors (RECIST) and circulating tumour DNA (ctDNA) are useful methods to measure patient response to treatment but do not enable the assessment of individual tumour lesions with high resolution.
In a new study published in Med, the potential of 68Ga-prostate-specific membrane antigen (PSMA) + 18F-fluorodeoxyglucose (FDG) paired positron emission tomography–computed tomography (PET–CT) was assessed to capture intralesional response heterogeneity (ILRH) and improve risk stratification in patients with mCRPC.
期刊介绍:
Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline.
The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals.
Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.